China’s 2026 Capital Policy Review: What It Means for Foreign Firms
China’s 2026 Capital Policy Review introduces 12 targeted adjustments to the 注册资本 (registered capital, zhùcè zīběn) framework, reducing minimum thresholds by 40% for manufacturing and R&D sectors while tightening compliance timelines for financial services. This review, published by the State Administration of Foreign Exchange (SAFE) and the Ministry of Commerce (MOFCOM), directly impacts the 68,000+ 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè) operating in China as of Q4 2025, marking the most significant capital policy shift since the 2020 Foreign Investment Law implementation.
Background: Why the 2026 Review Matters
Since 2020, foreign firms in China have navigated a dual pressure: rising operational costs in tier-1 cities and increased competition from domestic champions. From 2020 to 2025, the average registered capital for new WFOEs in manufacturing dropped 22%, from ¥14.2 million to ¥11.1 million, as investors adopted leaner structures. The 2026 review responds to this trend by formalizing lower capital minimums for specific sectors and introducing faster approval pathways for capital injections.
For context, in 2024, China approved ¥186.7 billion in foreign capital projects requiring SAFE approval — a 15% decline from the 2021 peak of ¥219.5 billion. The 2026 review aims to reverse that slide by reducing friction in capital deployment. According to MOFCOM data cited in the review, firms that completed capital repatriation under the old regime waited an average of 47 days for approval; the 2026 review targets 22 days for standard cases.
Key Changes in the 2026 Capital Policy Review
The review introduces three structural shifts that every foreign executive must understand. First, sector-specific capital thresholds replace the one-size-fits-all minimums. For manufacturing WFOEs in advanced industries (semiconductors, new energy, medical devices), the minimum registered capital drops from ¥10 million to ¥6 million — a 40% reduction. For software and R&D services, the minimum falls from ¥5 million to ¥3 million. Second, the review simplifies the 外汇管理 (foreign exchange administration, wàihuì guǎnlǐ) process for profit repatriation, reducing documentation from six items to three for firms with clean compliance records over the preceding 24 months. Third, a new “green lane” allows firms with registered capital above ¥50 million to execute capital increases within 5 business days, versus the previous 20-day minimum.
These changes do not apply uniformly. Financial services firms (banking, insurance, securities) face tighter timelines: capital injection approvals now require submission within 90 days of board resolution, down from 180 days. Non-compliance triggers a ¥50,000 to ¥200,000 administrative fine, plus a 12-month cooling-off period on new applications. This represents a 33% reduction in the grace window compared to the 2023 rules.
Sector-Specific Impacts for Foreign Firms
Manufacturing and Industrial WFOEs
Manufacturing firms benefit most from the capital threshold reductions. A mid-sized German automotive parts supplier establishing a WFOE in Jiangsu Province previously needed ¥10 million in registered capital. Under the 2026 review, ¥6 million suffices, freeing ¥4 million for operational expenditure or equipment imports. However, the review also mandates that 60% of registered capital must be physically injected within 12 months of business license issuance (up from 50% in 18 months previously). Firms that miss this deadline face a tiered penalty: 1% of the shortfall per month for underfunding between 60% and 80%, and 2% per month below 60%.
Software and R&D Service Centers
For software and R&D WFOEs — a category that includes multinational R&D centers in Shanghai, Beijing, and Shenzhen — the reduced ¥3 million minimum is a direct response to feedback from the American and European chambers of commerce. Between 2022 and 2025, 23% of new R&D WFOEs registered with capital below ¥5 million anyway, often via “soft capital” arrangements that local authorities tolerated but never formalized. The 2026 review legalizes this practice, but requires audited proof of R&D expenditure equivalent to at least 15% of registered capital annually for the first three years. Firms failing this metric must increase capital to ¥5 million by year four.
Financial Services and Regulated Industries
Financial services face the strictest changes. The review reduces the capital injection approval window from 180 to 90 days and introduces a new “source-of-funds” declaration requiring notarized evidence from the home-country regulator. A foreign bank establishing a branch in Shanghai now needs to submit PBOC China banking license pre-approval alongside the capital application — a step that adds 30–45 days to the timeline. SAFE data shows that in 2025, 17% of financial services capital applications were rejected or returned for incomplete documentation; the 2026 review aims to reduce this to under 10% by enforcing documentation completeness upfront.
Profit Repatriation and Cross-Border Capital Flows
The review’s changes to 利润汇出 (profit repatriation, lìrùn huìchū) are arguably its most practical impact for established foreign firms. Under the old rules, repatriation required: (1) audited financial statements, (2) tax clearance certificate, (3) board resolution, (4) capital account registration, (5) foreign exchange declaration, and (6) proof of tax payment. The 2026 review collapses this to three items for firms with a clean compliance record: audited statements, tax clearance, and board resolution — provided the firm has had zero foreign exchange penalties in the preceding 24 months. Firms with recent penalties still need all six items, plus a compliance review that adds 10–15 business days.
For firms repatriating ¥10 million or more annually — approximately 4,500 WFOEs based on SAFE 2025 data — the new rules also permit “batched” repatriation. Instead of applying per transaction, firms can submit a quarterly repatriation plan and execute up to three transfers within that plan without separate approvals. This reduces administrative overhead by an estimated 60% for high-volume repatriators. The first quarterly plan must be pre-approved; subsequent quarters only require notification 5 business days before the first transfer.
Comparative Analysis: 2024 vs 2025 vs 2026
| Policy Dimension | 2024 Rules | 2025 Rules | 2026 Review Changes |
|---|---|---|---|
| Minimum registered capital — manufacturing WFOE | ¥10 million | ¥10 million (no change) | ¥6 million (40% reduction) |
| Minimum registered capital — software/R&D WFOE | ¥5 million | ¥5 million | ¥3 million (40% reduction) |
| Capital injection approval timeline | 20 business days | 20 business days | 5 business days (green lane, for capital ≥¥50M) |
| Profit repatriation — required documents | 6 items | 6 items | 3 items (clean record firms only) |
| Capital injection grace period (manufacturing) | 50% in 18 months | 50% in 18 months | 60% in 12 months |
| Financial services capital approval window | 180 days | 180 days | 90 days |
| Average repatriation approval time | 47 days | 47 days | 22 days (target) |
| Penalty for late capital injection (per month) | 0.5% of shortfall | 0.5% of shortfall | 1%–2% (tiered) |
Decision Framework: Choosing Your Capital Structure Under the 2026 Review
If you are establishing a manufacturing WFOE for advanced industries with annual revenue projections below ¥50 million, choose the reduced ¥6 million minimum capital structure and plan for 60% injection within 12 months. This preserves ¥4 million for equipment or R&D instead of locking it in registered capital.
If you are a software or R&D service center with confirmed multi-year contracts from your parent company, choose the ¥3 million minimum but budget ¥450,000 (15%) in audited annual R&D spend to satisfy the review’s tracking requirement. If R&D spend is uncertain or will be below 15%, opt for ¥5 million capital upfront to avoid a forced increase in year four.
If you are a financial services firm with capital deployment needs exceeding ¥100 million, choose the green-lane pathway via a capital injection of ¥50 million+ to access the 5-day approval window. Accept the 90-day submission window from board resolution — calendar it immediately after board approval to avoid the 12-month cooling-off penalty.
3 Pitfalls in the 2026 Capital Policy Review
NEXT STEPS for Foreign Firms
- Audit your current capital structure against the 2026 thresholds. Review your WFOE’s registered capital, injection schedule, and sector classification. If your firm is overcapitalized relative to the new minimums, consider a capital reduction filing to free funds for operations or repatriation. See our WFOE registered capital optimization guide for step-by-step filing procedures.
- If repatriating profits in 2026, verify your 24-month FX compliance record. Request a compliance history report from your bank’s FX desk or from SAFE’s online portal. If clean, prepare for the three-item pathway by digitizing your audited statements and tax clearance certificates. Read our 2026 profit repatriation playbook for document checklists and timeline templates.
- For firms in financial services or regulated industries, calendar the 90-day capital injection window. If your board has approved a capital injection but not yet submitted, you have 90 days from the resolution date. Missing this window risks a 12-month freeze. Use our capital injection approval timeline tracker to manage deadlines across entities.
— China Gateway 360 —
Remote China market entry support, built around execution.
